Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma ...
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr ...
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients ...